{
  "generated_at": "2026-02-03T10:37:09Z",
  "company_id": "jnj",
  "company_name": "Johnson & Johnson",
  "asset_count": 45,
  "change_count": 557,
  "assets": [
    {
      "asset_id": 23,
      "asset_name": "(MajesTEC-4)",
      "aliases": [
        "(MajesTEC-4)"
      ],
      "indications": [
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Acute Myeloid Leukemia (cAMeLot-",
          "stage": "Registration",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 14,
      "asset_name": "(ORIGAMI-2)",
      "aliases": [
        "(ORIGAMI-2)"
      ],
      "indications": [
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Multiple Myeloma CD38 exposed",
          "stage": "Registration",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 34,
      "asset_name": "* JNJ-5120",
      "aliases": [
        "* JNJ-5120"
      ],
      "indications": [
        {
          "indication": "Major Depressive",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "Major Depressive",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 9,
      "asset_name": "Bleximenib",
      "aliases": [
        "Bleximenib"
      ],
      "indications": [
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Newly Diagnosed AML, with Venetoclax and",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 31,
      "asset_name": "CAPLYTA",
      "aliases": [
        "CAPLYTA",
        "CAPLYTA (lumateperone)",
        "lumateperone"
      ],
      "indications": [
        {
          "indication": "Pediatric Psychiatric",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "Pediatric Psychiatric",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 3,
      "asset_name": "CARVYKTI (Ciltacabtagene",
      "aliases": [
        "CARVYKTI (Ciltacabtagene"
      ],
      "indications": [
        {
          "indication": "Frontline Multiple",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Frontline Multiple",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 29,
      "asset_name": "Colitis",
      "aliases": [
        "Colitis",
        "Colitis (PURSUIT 2)",
        "PURSUIT 2"
      ],
      "indications": [
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 2",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 2",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 39,
      "asset_name": "Disorder",
      "aliases": [
        "Disorder"
      ],
      "indications": [
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "with Suicidal Ideation",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 10,
      "asset_name": "ERLEADA",
      "aliases": [
        "apalutamide",
        "ERLEADA",
        "ERLEADA (apalutamide)"
      ],
      "indications": [
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "ASCT Localized Prostate",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 38,
      "asset_name": "Gravis Pediatrics",
      "aliases": [
        "Gravis Pediatrics",
        "Gravis Pediatrics (VIBRANCE MG)",
        "VIBRANCE MG"
      ],
      "indications": [
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "Demyelinating Polyneuropathy",
          "stage": "Registration",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 30,
      "asset_name": "Hemolytic Anemia",
      "aliases": [
        "ENERGY",
        "Hemolytic Anemia",
        "Hemolytic Anemia (ENERGY)"
      ],
      "indications": [
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Alloimmune Thrombocytopenia",
          "stage": "Registration",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 1,
      "asset_name": "INLEXZO (gemcitabine",
      "aliases": [
        "INLEXZO (gemcitabine"
      ],
      "indications": [
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Non Muscle Invasive",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 33,
      "asset_name": "ITI-1284",
      "aliases": [
        "ITI-1284"
      ],
      "indications": [
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "Alzheimer's Disease-Related",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "with Generalized Anxiety",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 35,
      "asset_name": "Indications",
      "aliases": [
        "Indications"
      ],
      "indications": [
        {
          "indication": "for Major Depressive Disorder",
          "stage": "Phase 2",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "for Major Depressive Disorder",
          "stage": "Phase 2",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 36,
      "asset_name": "JNJ-1887​ sCD59",
      "aliases": [
        "JNJ-1887​ sCD59"
      ],
      "indications": [
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "Geographic Atrophy",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 15,
      "asset_name": "JNJ-1900",
      "aliases": [
        "JNJ-1900",
        "JNJ-1900 (NBTXR3)",
        "NBTXR3"
      ],
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 20,
      "asset_name": "JNJ-2175",
      "aliases": [
        "JNJ-2175"
      ],
      "indications": [
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Solid Tumors",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 16,
      "asset_name": "JNJ-2761",
      "aliases": [
        "JNJ-2761"
      ],
      "indications": [
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 17,
      "asset_name": "JNJ-4680",
      "aliases": [
        "JNJ-4680"
      ],
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 21,
      "asset_name": "JNJ-4681",
      "aliases": [
        "JNJ-4681"
      ],
      "indications": [
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Hematological Malignancies",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 28,
      "asset_name": "JNJ-4804 Co-antibody",
      "aliases": [
        "JNJ-4804 Co-antibody"
      ],
      "indications": [
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Crohn's Disease",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 18,
      "asset_name": "JNJ-5322",
      "aliases": [
        "JNJ-5322"
      ],
      "indications": [
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 22,
      "asset_name": "JNJ-7446",
      "aliases": [
        "JNJ-7446"
      ],
      "indications": [
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Lung Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 44,
      "asset_name": "MorphoSys AG; JNJ-2113: Protagonist Therapeutics;",
      "aliases": [
        "MorphoSys AG; JNJ-2113: Protagonist Therapeutics;"
      ],
      "indications": [
        {
          "indication": "and Memorial Sload Kettering; CARVYKTI: Legend XmAb CD28 bispecific antibodies; Xencor;",
          "stage": "Phase 3",
          "therapeutic_area": null,
          "as_of_date": null
        },
        {
          "indication": "and Memorial Sload Kettering; CARVYKTI: Legend XmAb CD28 bispecific antibodies; Xencor;",
          "stage": "Phase 3",
          "therapeutic_area": null,
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 5,
      "asset_name": "RYBREVANT",
      "aliases": [
        "amivantamab",
        "RYBREVANT",
        "RYBREVANT (amivantamab)"
      ],
      "indications": [
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Colorectal Cancer",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 43,
      "asset_name": "S I R T U R O",
      "aliases": [
        "S I R T U R O"
      ],
      "indications": [
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null,
          "as_of_date": null
        },
        {
          "indication": "L e p r o s y under review by regulatory bodies. Inclusion in the & Johnson assumes no obligation to update Long acting HIV injectible treatment regimen",
          "stage": "Phase 3",
          "therapeutic_area": null,
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 37,
      "asset_name": "SPRAVATO",
      "aliases": [
        "esketamine",
        "SPRAVATO",
        "SPRAVATO (esketamine)"
      ],
      "indications": [
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "Major Depressive Disorder Pediatrics",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 24,
      "asset_name": "STELARA",
      "aliases": [
        "STELARA",
        "STELARA (ustekinumab)",
        "ustekinumab"
      ],
      "indications": [
        {
          "indication": "Pediatric Juvenile",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Pediatric Juvenile",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 12,
      "asset_name": "TALVEY + TECVAYLI",
      "aliases": [
        "TALVEY",
        "TALVEY + TECVAYLI",
        "TECVAYLI"
      ],
      "indications": [
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 2,
      "asset_name": "TECVAYLI",
      "aliases": [
        "teclistamab",
        "TECVAYLI",
        "TECVAYLI (teclistamab)"
      ],
      "indications": [
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Multiple Myeloma",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Relapsed Refractory",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 25,
      "asset_name": "TREMFYA",
      "aliases": [
        "guselkumab",
        "TREMFYA",
        "TREMFYA (guselkumab)"
      ],
      "indications": [
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Pediatric Ulcerative",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Ulcerative Colitis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Pediatric Juvenile Psoriatic",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Pediatric Psoriasis",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 42,
      "asset_name": "UCL Business Plc; JNJ-1887: Hemera Biosciences;",
      "aliases": [
        "UCL Business Plc; JNJ-1887: Hemera Biosciences;"
      ],
      "indications": [
        {
          "indication": "and Mitsubishi Tanabe Pharma Corporation; TREMFYA: Genmab A/S; ERLEADA: Regents of California Genmab A/S; ENHANZE platform; Halozyme Therapeutics;",
          "stage": "Phase 2",
          "therapeutic_area": null,
          "as_of_date": null
        },
        {
          "indication": "and Mitsubishi Tanabe Pharma Corporation; TREMFYA: Genmab A/S; ERLEADA: Regents of California Genmab A/S; ENHANZE platform; Halozyme Therapeutics;",
          "stage": "Phase 2",
          "therapeutic_area": null,
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 41,
      "asset_name": "a c t o r X l a )",
      "aliases": [
        "a c t o r X l a )"
      ],
      "indications": [
        {
          "indication": "i o n through clinical trials as well as those to the best of the Company's knowledge. Johnson",
          "stage": "Phase 2",
          "therapeutic_area": null,
          "as_of_date": null
        },
        {
          "indication": "i o n through clinical trials as well as those to the best of the Company's knowledge. Johnson",
          "stage": "Phase 2",
          "therapeutic_area": null,
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 6,
      "asset_name": "autoleucel)",
      "aliases": [
        "autoleucel)"
      ],
      "indications": [
        {
          "indication": "Myeloma Transplant Eligible vs",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Myeloma Transplant Eligible vs",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 19,
      "asset_name": "bleximenib",
      "aliases": [
        "bleximenib"
      ],
      "indications": [
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Relapsed Refractory 1)",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 26,
      "asset_name": "icotrokinra",
      "aliases": [
        "icotrokinra"
      ],
      "indications": [
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Psoriatic Arthritis",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 7,
      "asset_name": "intravesical delivery",
      "aliases": [
        "intravesical delivery"
      ],
      "indications": [
        {
          "indication": "Bladder Cancer BCG-naïve",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Bladder Cancer BCG-naïve",
          "stage": "Phase 2",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 13,
      "asset_name": "intravesical delivery system)",
      "aliases": [
        "intravesical delivery system)"
      ],
      "indications": [
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Invasive Bladder Cancer BCG",
          "stage": "Registration",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 40,
      "asset_name": "m i l v e x i a n ( F",
      "aliases": [
        "m i l v e x i a n ( F"
      ],
      "indications": [
        {
          "indication": "A t r i a l F i b r i l l a t assets. The pipeline includes assets currently progressing This information is as of January 21, 2026 -milvexian: Bristol Myers Squibb; AAV-RPGR: Company, a subsidiary of Merck & Co., Inc. BTG International; DARZALEX and DARZALEX FASPRO: Duobody Platform bispecific antibody programs:",
          "stage": "Phase 1",
          "therapeutic_area": null,
          "as_of_date": null
        },
        {
          "indication": "A t r i a l F i b r i l l a t assets. The pipeline includes assets currently progressing This information is as of January 21, 2026 -milvexian: Bristol Myers Squibb; AAV-RPGR: Company, a subsidiary of Merck & Co., Inc. BTG International; DARZALEX and DARZALEX FASPRO: Duobody Platform bispecific antibody programs:",
          "stage": "Phase 1",
          "therapeutic_area": null,
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 27,
      "asset_name": "nipocalimab​",
      "aliases": [
        "nipocalimab​"
      ],
      "indications": [
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Hemolytic Disease",
          "stage": "Phase 1",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Fetal and Neonatal",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Warm Autoimmune",
          "stage": "Phase 3",
          "therapeutic_area": "Immunology",
          "as_of_date": null
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "Chronic Inflammatory",
          "stage": "Phase 3",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 4,
      "asset_name": "pasritamig",
      "aliases": [
        "pasritamig"
      ],
      "indications": [
        {
          "indication": "Prostate Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Prostate Cancer",
          "stage": "Phase 1",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 32,
      "asset_name": "seltorexant",
      "aliases": [
        "seltorexant"
      ],
      "indications": [
        {
          "indication": "Adjunctive Treatment Insomnia Symptoms",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        },
        {
          "indication": "Adjunctive Treatment Insomnia Symptoms",
          "stage": "Phase 1",
          "therapeutic_area": "Neuroscience",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 11,
      "asset_name": "system) INLEXZO (gemcitabine",
      "aliases": [
        "system) INLEXZO (gemcitabine"
      ],
      "indications": [
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "High Risk High Risk Non Muscle",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 8,
      "asset_name": "system) RYBREVANT",
      "aliases": [
        "amivantamab",
        "system) RYBREVANT",
        "system) RYBREVANT (amivantamab)"
      ],
      "indications": [
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        },
        {
          "indication": "Frontline Non Small",
          "stage": "Phase 3",
          "therapeutic_area": "Oncology",
          "as_of_date": null
        }
      ]
    },
    {
      "asset_id": 45,
      "asset_name": "y p e r t e n s i o n 7 5 m g",
      "aliases": [
        "U N I S U S",
        "y p e r t e n s i o n 7 5 m g",
        "y p e r t e n s i o n 7 5 m g ( U N I S U S )"
      ],
      "indications": [
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null,
          "as_of_date": null
        },
        {
          "indication": "pipeline is based on the current status of these this information. *AC Immune ACI-35.030. of rilpivirine and cabotegravir: ViiV Healthcare; Tau Immunotherapy: AC Immune SA; Biotech; AKEEGA: TESARO, an oncology- iPSC-derived chimeric antigen receptor",
          "stage": "Registration",
          "therapeutic_area": null,
          "as_of_date": null
        }
      ]
    }
  ]
}